NasdaqGS:ATNX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. More Details


Snowflake Analysis

High growth potential and slightly overvalued.

Share Price & News

How has Athenex's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ATNX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.3%

ATNX

-2.8%

US Biotechs

-5.3%

US Market


1 Year Return

-0.9%

ATNX

22.7%

US Biotechs

10.4%

US Market

Return vs Industry: ATNX underperformed the US Biotechs industry which returned 25% over the past year.

Return vs Market: ATNX underperformed the US Market which returned 12% over the past year.


Shareholder returns

ATNXIndustryMarket
7 Day0.3%-2.8%-5.3%
30 Day-5.1%-2.6%-2.1%
90 Day8.2%-2.5%1.7%
1 Year-0.9%-0.9%24.9%22.7%12.9%10.4%
3 Year-31.5%-31.5%14.3%8.6%34.3%25.4%
5 Yearn/a5.7%-2.0%73.7%54.3%

Price Volatility Vs. Market

How volatile is Athenex's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Athenex undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ATNX ($11.48) is trading below our estimate of fair value ($172.68)

Significantly Below Fair Value: ATNX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ATNX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ATNX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ATNX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ATNX is overvalued based on its PB Ratio (6.7x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Athenex forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

76.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATNX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: ATNX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ATNX's is expected to become profitable in the next 3 years.

Revenue vs Market: ATNX's revenue (40.7% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: ATNX's revenue (40.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ATNX's Return on Equity is forecast to be low in 3 years time (0.5%).


Next Steps

Past Performance

How has Athenex performed over the past 5 years?

-9.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ATNX is currently unprofitable.

Growing Profit Margin: ATNX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ATNX is unprofitable, and losses have increased over the past 5 years at a rate of 9.8% per year.

Accelerating Growth: Unable to compare ATNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.8%).


Return on Equity

High ROE: ATNX has a negative Return on Equity (-93.44%), as it is currently unprofitable.


Next Steps

Financial Health

How is Athenex's financial position?


Financial Position Analysis

Short Term Liabilities: ATNX's short term assets ($216.6M) exceed its short term liabilities ($66.9M).

Long Term Liabilities: ATNX's short term assets ($216.6M) exceed its long term liabilities ($104.9M).


Debt to Equity History and Analysis

Debt Level: ATNX's debt to equity ratio (75.7%) is considered high.

Reducing Debt: ATNX's debt to equity ratio has increased from 2.9% to 75.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ATNX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ATNX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 25.7% each year


Next Steps

Dividend

What is Athenex current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ATNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ATNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ATNX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ATNX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ATNX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

  • Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Johnson Lau (60 yo)

9.75yrs

Tenure

US$4,483,836

Compensation

Dr. Yiu-Nam Lau, also known as Johnson, MBBS, MD, FRCP, Ph.D., has been the Chief Executive Officer of Athenex, Inc. since 2011. Dr. Lau is the Vice Chairman and CEO of Axis Therapeutics. Dr. Lau serves as ...


CEO Compensation Analysis

Compensation vs Market: Johnson's total compensation ($USD4.48M) is above average for companies of similar size in the US market ($USD2.96M).

Compensation vs Earnings: Johnson's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Yiu-Nam Lau
Chairman & CEO9.75yrsUS$4.48m3.55%
$ 38.0m
Randoll Sze
Chief Financial Officer2.17yrsUS$942.99k0.0064%
$ 68.8k
Jeffrey Yordon
COO & President of Athenex Pharmaceutical Division3.58yrsUS$1.39m0.25%
$ 2.7m
Rudolf Kwan
Chief Medical Officer6.75yrsUS$1.47m0.15%
$ 1.6m
Simon Pedder
Chief Business & Strategy Officer of Proprietary Products3.58yrsUS$860.55k0.0057%
$ 60.9k
Allen Barnett
Co-Founder & President Emeritus9.75yrsno datano data
Teresa Bair
General Counsel1.83yrsno datano data
Jacqueline Li
Director of Corporate Development & Investor Relationsno datano datano data
Daniel Lang
Senior Director of Corporate Development1.75yrsno datano data
John Matthei
Vice President of Human Resourcesno datano datano data
Wing-Kai Chan
Deputy Chief Medical Officer of Orascovery & Src Kinase Platformsno datano datano data
E. Kramer
Senior Vice President of Clinical Pharmacovigilance & Regulatory Affairs0.75yrno datano data

3.6yrs

Average Tenure

60yo

Average Age

Experienced Management: ATNX's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Yiu-Nam Lau
Chairman & CEO9.75yrsUS$4.48m3.55%
$ 38.0m
John Vierling
Independent Director1.5yrsUS$114.74k0.0019%
$ 20.7k
Jinn Wu
Independent Director13.5yrsUS$149.96k0.43%
$ 4.6m
Robert Spiegel
Director0.17yrno datano data
Kwan-Hung Tsang
Independent Director2.25yrsUS$184.04k0.011%
$ 114.8k
Jordan Kanfer
Independent Director1.5yrsUS$117.74k0.0050%
$ 53.2k
Manson Fok
Director5.33yrsUS$105.81k2.14%
$ 23.0m
Kim Campbell
Lead Independent Director3.83yrsUS$151.96k0%
$ 0
Stephanie Davis
Independent Director1.5yrsUS$156.24k0.021%
$ 229.6k

2.3yrs

Average Tenure

63yo

Average Age

Experienced Board: ATNX's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ATNX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.6%.


Top Shareholders

Company Information

Athenex, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Athenex, Inc.
  • Ticker: ATNX
  • Exchange: NasdaqGS
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.070b
  • Shares outstanding: 93.24m
  • Website: https://www.athenex.com

Number of Employees


Location

  • Athenex, Inc.
  • Conventus Building
  • Suite 600
  • Buffalo
  • New York
  • 14203
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ATNXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 2017
2MTDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2017

Biography

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. I ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/30 03:25
End of Day Share Price2020/10/29 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.